Montelukast in childhood asthma: what is the evidence for its use?

References

• Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med.323, 645–655 (1990).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Frew AJ. Choosing therapy for childhood asthma. N. Engl. J. Med.337, 1690–1692 (1997).
   PubMed Web of Science ®Google Scholar
• Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med.323, 645–655 (1990).
   PubMed Web of Science ®Google Scholar
• Lougheed DM, Lemiere C, Dell SD et al. Canadian Thoracic Society asthma continuum – 2010 consensus summary for children six years of age and over, and adults. Can. Respir. J.17(1), 15–24 (2010).
   PubMed Web of Science ®Google Scholar
• Kovesi T, Schuh S, Spier S et al. Achieving control of asthma in preschoolers. Can. Med. Assoc.18(4), 173–182 (2010).
   Google Scholar
• To T, Dell S, Dick PT et al. Case verification of children with asthma in Ontario. Pediatr. Allergy Immunol.17, 69–76 (2006).
   PubMed Web of Science ®Google Scholar
• Martinez FD. Trends in asthma prevalence, admission rates and asthma deaths. Respir. Care53, 561–565 (2008).
   PubMed Web of Science ®Google Scholar
• Harmanci K. Montelukast: its role in the treatment of childhood asthma. Ther. Clin. Risk Man.3(5), 885–892 (2007).
   PubMedGoogle Scholar
• Wright AL, Taussig LM. Lessons from long term cohort studies: childhood asthma. Eur. Respir. J.27(Suppl.), 17S–22S (1998).
   Google Scholar
• Masoli M, Fabian D, Holt S et al. The global burden of asthma: exec sum of the GINA dissemination committee report. Allergy59, 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Benninger MS, Waters H. Montelukast: pharmacology, safety, tolerability and efficacy. Clin. Med. Ther.1, 1253–1261 (2009).
   Google Scholar
• Pawankar R. Allergic rhinitis and asthma: the link, the new ARIA classification and global approaches to treatment. Curr. Opin. All. Clin. Immunol.4(1), 1–4 (2004).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv. Ther.26(6), 575–587 (2009).
   PubMedGoogle Scholar
• Cowie RL, Underwood, MF, Feild SK. Inhaled CS therapy does not control asthma. Can. Respir. J.11, 555–558 (2004).
   Google Scholar
• Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M et al. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr. Pulmonol.41(3), 222–227 (2006).
   PubMed Web of Science ®Google Scholar
• Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J. Pediatr.73(4), 276–282 (2006).
   Google Scholar
• Cheng H, Leff JA, Amin R et al. Pharmacokinetics, bioavailability and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm. Res.13, 445–448 (1996).
   PubMed Web of Science ®Google Scholar
• Garcia ML, Wahn U, Gilles L et al. Montelukast, compared with fluticasone, for control of asthma among 6-to14 year-old patients with mild asthma: the MOSAIC study. Pediatrics116(2), 360–369 (2005).
   PubMed Web of Science ®Google Scholar
• Ostrom NK, Decotiis BA, Lincourt WR et al. Comparative efficacy and safety of low-dose fluticasone proprionate and montelukast in children with persistent asthma. J. Pediatr.147, 213–220 (2005).
   PubMed Web of Science ®Google Scholar
• Szelfer SJ, Phillips B, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol.115, 592–597 (2005).
   Google Scholar
• Sorkness CA, Lemanske RF, Mauger DT et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J. Allergy Clin. Immunol.119, 64–72 (2007).
   PubMed Web of Science ®Google Scholar
• Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild–moderate asthma: systematic review with meta-analysis. Arch. Dis. Child.95(5), 365–367 (2010).
   PubMed Web of Science ®Google Scholar
• Ducharme FM, di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst. Rev.3, CD002314 (2000).
   Google Scholar
• Ducharme FM. Inhaled glucocorticoids versus leukotrienes receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J.326, 1–5 (2003).
   Google Scholar
• Todd GR, Acerini CL, Ross-Russell R et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch. Dis. Child.121, E1–E14 (2008).
   Google Scholar
• Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med.343, 1064–1069 (2000).
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2-to 5-year old children with intermittent asthma. Am. J. Respir. Crit. Care Med.171, 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Bisgaard H. Randomized trial of montelukast in respiratory syncytial virus post-bronchiolitis. Am. J. Respir. Crit. Care Med.167, 379–383 (2003).
   PubMed Web of Science ®Google Scholar
• Robertson CF, Price D, Henry R et al. Short course montelukast for intermittent asthma in children: a randomized controlled trial. Am. J. Respir. Crit. Care Med.354, 1998–2005 (2006).
   Google Scholar
• Johnston NW, Mandhane PJ, Dai J et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized controlled trial of montelukast added to usual therapy. Pediatrics120(3), 3702–3712 (2007).
   Google Scholar
• Weiss KB, Gern JE, Johnson NW et al. The back to school asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year. Ann. Allergy Asthma Immunol.104(6), 511–517 (2010).
   Google Scholar
• British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Thorax63(Suppl. 4), IV1–IV121 (2008).
   PubMed Web of Science ®Google Scholar
• Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst. Rev.3, CD003133 (2002).
   Google Scholar
• Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6-to 14-year old children: a randomized double-blind trial. Pediatric Montelukast Study Group. JAMA279(15), 1181–1186 (1998).
   PubMed Web of Science ®Google Scholar
• Simons FE, Villa JR, Teper AM et al. Montelukast added to budesonide in children with persistent asthma. A randomized, double-blind, crossover study. J. Pediatr.138(5), 694–698 (2001).
   PubMed Web of Science ®Google Scholar
• Jat GC, Mathew JL, Singh M. Treatment with 400 mcg of inhaled budesonide versus 200 mcg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: a randomized control trial. Ann. Allergy Asthma Immunol.97(3), 397–401 (2006).
   PubMed Web of Science ®Google Scholar
• Miraglia del Guidice M, Piacentini GL, Capasso M et al. Fomoterol, montelukast and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respir. Med.101(8), 1809–1813 (2007).
   Google Scholar
• Lemanske RF, Mauger DT, Sorkness CA et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med.362(11), 975–985 (2010).
   PubMed Web of Science ®Google Scholar
• Stelmach I, Korzeniewska A, Smejda K et al. Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis. Pneumonol. Alergol. Pol.72, 85–89 (2004).
   PubMedGoogle Scholar
• Carraro S, Carradi M, Zanconato S et al. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol.115, 764–770 (2005).
   PubMed Web of Science ®Google Scholar
• Montuschi P, Mondino C, Koch P et al. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J. Allergy Clin. Immunol.118, 347–353 (2006).
   PubMed Web of Science ®Google Scholar
• Fogul RB, Rosario N, Aristizabal G et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann. Allergy Asthma Immunol.104(6), 511–517 (2010).
   Google Scholar
• Wenzel SE. Antileukotriene drugs in the management of asthma. JAMA280, 2068–2069 (1998).
   PubMed Web of Science ®Google Scholar
• Herland K, Akselsen JP, Skjonsberg OH et al. How representative are clinical study patients with asthma or COPD for a larger ‘real life’ population of patients with obstructive lung disease? Respir. Med.99, 11–19 (2005).
   PubMed Web of Science ®Google Scholar
• Dupont L, Potvin E, Korn D. Improving asthma control in patients suboptimally controlled on inhaled steroids and long acting β agonists: the addition of montelukast in an open-label pilot study. Curr. Med. Res. Opin.21(6), 863–942 (2005).
   PubMed Web of Science ®Google Scholar
• Korn D, Van den Brande D, Potvin E et al. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open label study. Curr. Med. Res. Opin.25(2), 489–497 (2009).
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Foucart S, Coyle S et al. Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial). Can. Respir. J.16, 5A–14A (2009).
   Google Scholar
• Virchow JC, Mehta A, Ljungblad L, Mitfessel H. Add-on montelukast in inadequately controlled asthma patients in a 6 month open label study: the montelukast in chronic asthma (MONICA) study. Respir. Med.104(5), 644–651 (2010).
   PubMed Web of Science ®Google Scholar
• Schlick W, Pohl W, Pfeiffer KP et al. Evaluation of 3–5 months’ add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real world, observational study. Curr. Med. Res. Opin.26(3), 561–570 (2010).
   PubMed Web of Science ®Google Scholar
• McIvor RA, Kaplan A, Koch C, Sampalis JS. Montelukast as an alternative to low-dose inhaled corticosteroids in the management of mild asthma (the SIMPLE trial): an open-label effectiveness trial. Can. Respir J.16, 11A–21A (2009).
   Google Scholar
• Keith PK, Koch C, Djandji M et al. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long acting β-2-agonist in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trail). Can. Respir. J.16(Suppl. A), 17A–24A (2009).
   PubMedGoogle Scholar
• Riccioni G, Bucciarelli T, Mancini B et al. Antileukotriene drugs: clinical application, effectiveness and safety. Curr. Med. Chem.14, 1966–1977 (2007).
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Finn D, Gunawardena D et al. Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest117, 708–713 (2000).
   PubMed Web of Science ®Google Scholar
• Manalai P, Woo JM, Postolache TT. Suicidality and montelukast. Opin. Drug Saf.8, 273–282 (2009).
   PubMed Web of Science ®Google Scholar
• Scadding GW, Scadding GK. Recent advances in antileukotriene therapy. Curr. Opin. Allergy Clin.10(4), 370–376 (2010).
   Google Scholar